ARS Pharma Collapses After CVS Punts Its Epinephrine Spray Decision To January
Licensing
10:04 AM ET 06/25/2026
ARS Pharmaceuticals (SPRY) stock collapsed Thursday after CVS Caremark declined to add its epinephrine spray, Neffy, to its formulary ahead of a July 1 deadline. The decision came as a "negative shock given management's prior guidance towards reaching a potential agreement in time and updates suggesting positive progress on the contract," William Blair analyst Lachlan Hanbury-Brown said in a note…
